Armata Pharmaceuticals (ARMP) Cash from Financing Activities (2013 - 2026)

Armata Pharmaceuticals has disclosed Cash from Financing Activities across 13 years of filings, most recently posting $641000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $641000.0, down 93.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (up 62.46% YoY), and the FY2025 annual result was $25.6 million, down 26.73% from the prior year.
• Cash from Financing Activities came in at $641000.0 for Q1 2026 at Armata Pharmaceuticals, down from $658000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $44.6 million in Q1 2022 to a low of -$500000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $641000.0 (2026), against an average of $10.6 million.
• Peak annual rise in Cash from Financing Activities reached 79916.13% in 2023, while the deepest fall reached 152.05% in 2023.
• Armata Pharmaceuticals' Cash from Financing Activities stood at -$500000.0 in 2022, then jumped by 91.4% to -$43000.0 in 2023, then sank by 41.86% to -$61000.0 in 2024, then soared by 1178.69% to $658000.0 in 2025, then fell by 2.58% to $641000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $641000.0 (Q1 2026), $658000.0 (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.